ConcertAI

Join us next week at the 2024 ISPE Annual Meeting in Berlin on August 28th from 8:00 AM – 1:30 PM for a fascinating poster session presented by AbbVie. Dive into the world of "Unlocking Insights: Lessons Learned from the Tokenization of a Psoriasis Trial" By generating unique patient IDs from personal identifying information, tokenization allows for the seamless integration of clinical trial data with real-world data (RWD), enhancing the capture of comorbidities and drug exposure before a trial even begins. In a recent pilot study using ConcertAI’s claims dataset, researchers successfully integrated trial data with RWD through tokenization, providing valuable insights into the baseline characteristics of trial participants. The results showed a high overlap between trial participants and information in open claims, with some discrepancies noted in closed claims. Despite minor discrepancies in baseline comorbidities between the RCT and RWD populations, the integration of data through tokenization has opened up new possibilities for understanding patient profiles and treatment outcomes. These initial findings highlight the potential of tokenization in bridging the gap between clinical trial data and real-world evidence. Read the abstract to learn more: https://hubs.ly/Q02M6b1D0 #Tokenization #HealthcareResearch #DataIntegration #ClinicalTrials #RWD #HIPAACompliant #PatientID #InnovativeResearch #ISPE2024

We are very excited to be presenting an oral presentation next week at the ISPE 2024 Annual meeting. Join us Wednesday, August 28th from 8:30-8:45 AM to hear this presentation live. The objective of this study is to use features from structured and unstructured EHR data to create an Integrated Machine Learning (IML) model to determine the date of metastatic diagnosis of cancer with high accuracy. Natural Language Processing (NLP) is a promising technique to enrich real world data (RWD) by extracting information from unstructured EHR documents. Accurately extracting event dates like dates of metastasis or progression with NLP remains an open research area due to the variety of ways dates are recorded in the real world. Simultaneously, structured data from RWD sources like EHR and Claims provide an array of features informing a patients’ journey. Metastatic diagnosis is a life changing medical event that triggers fundamental changes in patterns of care. We see this reflected in the lab reports, medications, and clinical evidence mentioned in doctor reports. Through extraction of these features, we built an IML model to refine NLP dates from a set of candidates. This work leverages ConcertAI’s industry leading multi-modal oncology data repository, representing more than 8 million patients, covering all 50 states. Combined it enables precision oncology solutioning at scale for problems such as outcome analysis, real world evidence studies, and treatment sequencing optimization. Learn more: https://hubs.ly/Q02LSNr80 Presenting Author: Vivek Vaidya Authors: Vandana Priya, Urvashi (Raheja) Bhattacharyya PhD, Sheenu Chandwani, Herman E. Ray PhD, Srikanth Tankala, Jake Cohen #ISPE2024 #MachineLearning #OncologyResearch #NLP #PrecisionMedicine

Congratulations to Amy Alabaster and Yanina (Yana) Natanzon on their manuscript collaboration with Friends of Cancer Research among other partners in the JCO Clinical Cancer Informatics, American Society of Clinical Oncology (ASCO). This publication demonstrates the feasibility of aligning disparate real-world (rw) data sources to evaluate rw-response to treatment using clinician-documented response in patients with metastatic non-small cell lung cancer (mNSCLC). Alignment of methodologies analyzing real-world data (RWD) is critical for supporting evidence generation using these data RWD to inform oncology drug development and regulatory decision-making. These findings are from the latest pilot project in Friends’ Real-World Evidence Portfolio which establishes methodologies for using real-world data (RWD) to evaluate safety and efficacy of therapies for patients. Read "Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in mNSCLC patients treated with chemotherapy” here: https://hubs.ly/Q02LJDYb0 #RWEFriends #publication #patients #RWD #EHR

Join the poster session at the 2024 ISPE Annual Meeting in Berlin on August 27th from 8:00 AM – 6:00 PM for a presentation titled: "Representativeness of race, ethnicity and social determinants of health in patients with advanced non-small cell lung cancer via linkage of real-world electronic health records, administrative claims, and consumer financial data," presented by AbbVie. Social determinants of health (SDOH) play a crucial role in driving health disparities and impacting clinical research participation among underserved populations. Diversity plans in cancer clinical trials are working to reduce disparities and improve representation through real-world data (RWD). Using ConcertAI’s electronic health record (EHR) database, this study focused on patients with advanced non-small cell lung cancer (aNSCLC) to assess representation based on race, ethnicity, and SDOH. The study found that patients with linked SDOH data were more likely to be non-Hispanic White, had lower levels of education, and lower individual income compared to those without linked SDOH data. These findings highlight the importance of addressing representativeness gaps in clinical trials to ensure equitable access to healthcare. Read the abstract to learn more: https://hubs.ly/Q02LyrkP0 #HealthEquity #ClinicalResearch #SDOH #RepresentationMatters #ISPE2024

We are just one month away from the 2024 ESMO Congress in Barcelona, Spain and ConcertAI will be there! We can't wait to deepen connections and share insights on the complexities and opportunities in medical oncology. Schedule a meeting with us to learn how ConcertAI is using Real World Data to tackle the toughest challenges in drug development. Let's chat and discover how we can work together to drive innovation in Life Sciences. Schedule a time to chat with us: https://hubs.ly/Q02LbqNf0 #ESMO2024 #RealWorldData #MedicalOncology #Innovation #DrugDevelopment

Are you passionate about making a difference in cancer care? ConcertAI is looking for dedicated team members who share our vision of advancing quality, diversity, and efficiency in cancer treatment. We have a range of exciting opportunities available, with perks like work-life flexibility, comprehensive medical benefits, generous PTO and parental leave. If you're ready to join a dynamic team and make a meaningful impact, check out our open positions here: https://hubs.ly/Q02KN07c0 #CancerCare #JoinOurTeam #CareerOpportunities #Hiring

The 2024 ISPE Annual Meeting in Berlin is just a little over two weeks away, and our team is gearing up to showcase how we use real-world data and AI to drive breakthroughs in Pharmacoepidemiology. Schedule a time to chat with us and learn more about our innovative approach: https://hubs.ly/Q02KvFp90 #ISPEAnnualMeeting #Pharmacoepidemiology #RealWorldData #AI

Today is World Lung Cancer Day. We stand with Lung Cancer survivors and join in support to raise awareness and defeat the stigma associated with the disease. At ConcertAI, we’re deeply committed to advancing lung cancer research. Our most recent study done in collaboration with Merck was a retrospective analysis on the treatment patterns and survival outcomes of early-stage non-small cell lung cancer (NSCLC) patients following complete resection. The study, analyzing electronic medical records from the ConcertAI Patient360™ database, sheds light on adjuvant treatment patterns, overall survival, and real-world disease-free survival in patients with stage IB-IIIA NSCLC. Real-world data from 441 patients showed the importance of adjuvant chemotherapy in improving long-term survival outcomes for NSCLC patients. Despite the low usage of adjuvant chemotherapy, patients who remained disease-free over time showed favorable long-term survival rates. Learn more: https://hubs.ly/Q02JKPZB0 #LungCancerResearch #Collaboration #CancerSurvival #MedicalResearch #WLCD24 #WorldLungCancerDay

We are excited to participate in the 2024 ISPE Annual Meeting in Berlin, Germany, next month! Join us to learn how ConcertAI is revolutionizing the field of Pharmacoepidemiology through the innovative combination of real-world data and artificial intelligence. Schedule a time to chat: https://hubs.ly/Q02J0j820 #ISPEAnnualMeeting #ConcertAI #Pharmacoepidemiology #AI

Genomic testing plays a crucial role in enhancing our understanding of tumors by uncovering key details like molecular variants, fusions, and copy number abnormalities. These mutation profiles are especially valuable when comparing specimens before and after specific lines of therapy to track changes in tumor cells, including the development of resistant populations. By collaborating with innovative clinical laboratories and technology leaders, we can combine our data with various sources like radiological images, digital pathology, whole transcriptome/whole exam/whole slide images, longitudinal liquid biopsies, and comprehensive monitoring of hematological malignancies. Learn more about Genome360™: https://hubs.ly/Q02GPvFN0 #GenomicTesting #TranslationalSciences #DataPartnerships #InnovativeTherapies #ResearchCollaboration